Press Releases

Bitget Delivers Critical Aid to Earthquake-Affected Families in Myanmar BANGKOK, May 12, 2025 (GLOBE NEWSWIRE) — Bitget, the leading cryptocurrency exchange and Web3 company, has mobilized relief efforts for vulnerable communities in Myanmar following the devastating 7.7 magnitude earthquake that

WATERFORD, Ireland, May 12, 2025 (GLOBE NEWSWIRE) — Minimum Deposit Casinos (MDC), a leading global online casino review hub and division of the OneTwenty Group, has released new insights into the tightening regulatory landscape for sweepstakes-based gaming in the United

Bitget Announces Strategic Partnership with SWEAT to Boost Movement Economy in Web3 DUBAI, United Arab Emirates, May 09, 2025 (GLOBE NEWSWIRE) — Bitget, the leading cryptocurrency exchange and Web3 company, has announced its strategic partnership with SWEAT, the pioneering movement

BEIJING, May 08, 2025 (GLOBE NEWSWIRE) — A natural gas pipeline that stretches 3,000 kilometers in Russia and 5,111 km in China commenced operations in December last year, benefiting about 450 million people along its route. The China-Russia east-route natural

HOHHOT, China, May 08, 2025 (GLOBE NEWSWIRE) — On April 29, Inner Mongolia Yili Industrial Group Co., Ltd. (600887.SH) released its financial results, reporting total revenue of 115.78 billion yuan in FY2024, further solidifying its position as Asia’s top dairy

ZURICH, May 08, 2025 (GLOBE NEWSWIRE) — The European Academy of Allergy & Clinical Immunology (EAACI), in partnership with the Hong Kong Institute of Allergy (HKIA), is proud to announce the inaugural EAACI Hong Kong Allergy School. This significant milestone

Unified Engagement from Zoom CX and ServiceNow integrates voice, video, and digital channels directly within the ServiceNow AI Platform for a simpler agent experience and more personalized customer engagements LAS VEGAS, May 07, 2025 (GLOBE NEWSWIRE) — Zoom Communications Inc.

Freiburg, May 7th, 2025 Study results demonstrate superiority of norucholic acid (NCA) over placebo in the combined primary endpoint. There is currently no approved medicine to treat primary sclerosing cholangitis. The results of the 96-week analysis of the NUC-5 trial